PHG Lowers 2020 Outlook After U.S. Cancels Ventilator Order

The stock has been testing support at its year-to-date breakeven

Digital Content Manager
Aug 31, 2020 at 8:59 AM
facebook twitter linkedin

The shares of Netherlands-based health technology company Koninklijke Philips NV (NYSE:PHG) have taken a hit this morning, following news that the U.S. government just cancelled a bulk order of 43,000 EV300 ventilators, driving the firm to lower its 2020 earnings outlook. This move comes just a few months after a July report by the U.S. Congress House Subcommittee on Economic and Consumer Policy revealing that the White House overpaid for this order by at least $500 million, though the company denied any profiteering. At last check, PHG is down 3% at $47.78. 

Despite July's dispute, PHG was able to overtake long-time pressure at the $50 mark to reach a fresh high of $54.28 on July 29. The stock has since cooled, dipping back below this region earlier this month. Now, the equity is looking to close back below its 70-day moving average -- a trendline that provided some support back in May. The stock is also testing its footing back at its year-to-date breakeven near the $48 level. 

While only three analysts cover the medical stock, two give it a "strong buy" rating, compared to just one "hold." The 12-month consensus price target of $53.75, meanwhile, is a 13.1% premium to last night's close. 

Short sellers have started piling on the stock. In fact, short interest rose 16.6% in the last reporting period. There's still plenty of room on the bearish bandwagon, however. The 1.19 million shares sold short make up a slim 0.1% of PHG's available float, or a little over two days at the stock's average pace of trading. 


If you are not making money with options, you aren’t buying options like this…

There is no options strategy that more perfectly approaches trading the fastest moving and most volatile stocks available in the marketplace than this one. In fact, there is no strategy that better utilizes put options for optimal returns and a real trading edge over other traders in the exact same market. New options traders fail out at an incredible rate without proper trade research, execution timing, and option picking. Capitalize on Schaeffer’s 100+ years of options trading excellence with the most coveted product launch in company history. Don't waste another second... join us right now before the next round of trades are released!

Schaeffer's Investment Research Stock Pick Report


Special Offers from Schaeffer's Trading Partners